Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Ansari, Marc  [Clear All Filters]
2013
Ansari M, Uppugunduri CRao S, Ferrari-Lacraz S, Bittencourt H, Gumy-Pause F, Chalandon Y, Tiercy J-M, Schechter T, Gassas A, Doyle JD, et al. The Clinical Relevance of Pre-Formed Anti-HLA and Anti-MICA Antibodies after Cord Blood Transplantation in Children. PLoS One. 2013;8(8):e72141.
2020
Koenig C, Bodmer N, Agyeman PKA, Niggli F, Adam C, Ansari M, Eisenreich B, Keller N, Leibundgut K, Nadal D, et al. 39·0°C versus 38·5°C ear temperature as fever limit in children with neutropenia undergoing chemotherapy for cancer: a multicentre, cluster-randomised, multiple-crossover, non-inferiority trial. Lancet Child Adolesc Health. 2020.
Bradford KL, Liu S, Krajinovic M, Ansari M, Garabedian E, Tse J, Wang X, Shaw KL, H Gaspar B, Candotti F, et al. Busulfan Pharmacokinetics in ADA SCID Gene Therapy. Biol Blood Marrow Transplant. 2020.
Strahm B, Loewecke F, Niemeyer CM, Albert M, Ansari M, Bader P, Bertrand Y, Burkhardt B, Da Costa LM, Ferster A, et al. Favorable outcomes of hematopoietic stem cell transplantation in children and adolescents with Diamond-Blackfan anemia. Blood Adv. 2020;4(8):1760-1769.
Cesaro S, Pillon M, Sauer M, Smiers F, Faraci M, de Heredia CDíaz, Wynn R, Greil J, Locatelli F, Veys P, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for Shwachman-Diamond syndrome: a retrospective analysis and a review of the literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Tra. Bone Marrow Transplant. 2020.
Willasch AManfred, Peters C, Sedlacek P, Dalle J-H, Kitra-Roussou V, Yeşilipek A, Wachowiak J, Lankester A, Prete A, Hamidieh AAli, et al. Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-A multicenter EBMT-PDWP study. Bone Marrow Transplant. 2020.
2021
Waespe N, Belle FN, Redmond S, Schindera C, Spycher BD, Rössler J, Ansari M, Kuehni CE. Cancer predisposition syndromes as a risk factor for early second primary neoplasms after childhood cancer - A national cohort study. Eur J Cancer. 2021;145:71-80.
Mlakar SJurkovic, Uppugunduri SChakradhar, Nava T, Mlakar V, Golay H, Robin S, Waespe N, Rezgui MAziz, Chalandon Y, Boelens JJan, et al. Correction to: GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation. J Cancer Res Clin Oncol. 2021.
2022
Hendrikse LD, Haldipur, iv P, Saulnier O, Millman J, Sjoboen AH, Erickson AW, Ong W, Gordon V, Coudière-Morrison L, Mercier AL, et al. Author Correction: Failure of human rhombic lip differentiation underlies medulloblastoma formation. Nature. 2022.
Chalandon Y, Mamez A-C, Giannotti F, Beauverd Y, Dantin C, Mahne E, Mappoura M, Bernard F, Ortiz Cde Ramon, Stephan C, et al. DEFIBROTIDE SHOWS EFFICACY IN THE PREVENTION OF SINUSOIDAL OBSTRUCTION SYNDROME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY ON 237 PATIENTS. Transplant Cell Ther. 2022.
2023
Kasteler R, Otth M, Halbeisen FS, Mader L, Singer F, Rössler J, von der Weid NX, Ansari M, Kuehni CE. Longitudinal assessment of lung function in Swiss childhood cancer survivors-A multicenter cohort study. Pediatr Pulmonol. 2023.
Bader P, Poetschger U, Dalle J-H, Moser LM, Balduzzi ACristina, Ansari M, Buechner J, Güngör T, Ifversen M, Kriván G, et al. Low rate of nonrelapse mortality in under 4-year-olds with ALL given chemo-conditioning for HSCT: Phase III FORUM study. Blood Adv. 2023.
Waespe N, Mlakar SJurkovic, Dupanloup I, Rezgui MAziz, Bittencourt H, Krajinovic M, Kuehni CE, Nava T, Ansari M. A novel integrative multi-omics approach to unravel the genetic determinants of rare diseases with application in sinusoidal obstruction syndrome. PLoS One. 2023;18(4):e0281892.
Ben Hassine K, Seydoux C, Khier S, Daali Y, Medinger M, Halter J, Heim D, Chalandon Y, Schanz U, Nair G, et al. Pharmacokinetic modeling and simulation with pharmacogenetic insights support the relevance of therapeutic drug monitoring for myeloablative busulfan dosing in adult HSCT. Transplant Cell Ther. 2023.